Effective October 05, 2022, lisinopril, benazepril, chlorthalidone, furosemide (Lasix®), hydrochlorothiazide (HCTZ), lisinopril plus HCTZ (Zestoretic®), losartan (Cozaar®), and losartan plus HCTZ (Hyzaar®) have been added to the ADAP formulary.
Hypertension is a leading modifiable risk factor for mortality among adults with HIV on antiretroviral therapy (ART). In addition, adults who are 50 years or older with HIV are 50 percent more likely to have hypertension than people over 50 years without HIV. Hypertension when left untreated may lead to heart valve problems, heart failure, heart rhythm issues, stroke, and heart attack. The incidence of heart disease among adults with HIV is twice the incidence as in the general population, highlighting the need to address hypertension as a modifiable risk factor for heart disease. The addition of these medications provides options to ensure that ADAP clients receive care consistent with current national guidelines to manage cardiovascular risk factors and prevent heart disease.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of lisinopril, benazepril, chlorthalidone, furosemide (Lasix®), hydrochlorothiazide (HCTZ), lisinopril plus HCTZ (Zestoretic®), losartan (Cozaar®), and losartan plus HCTZ (Hyzaar®).
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).
Sharisse Kemp, MSW
ADAP Branch Chief
California Department of Public Health